Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: DanielleC who wrote (21733)	3/2/2000 2:41:00 PM
From: Jules	Respond to of 25711

Perrigo Company Receives Approval to Market Acetaminophen Extended Release Tablets ALLEGAN, Mich., March 2 /PRNewswire/ -- The Perrigo Company (Nasdaq: PRGO - news) today announced that it has received approval from the Food and Drug Administration (FDA) to manufacture and market acetaminophen extended release tablets, 650 mg, effective immediately. The Company anticipates initial shipments in its fourth quarter ending July 1, 2000. The FDA concluded that acetaminophen extended release tablets produced by Perrigo are safe and effective and bioequivalent to Tylenol© Arthritis Extended Relief Caplets marketed by McNeil Consumer Products Company. The approval was granted through the Abbreviated New Drug Application (ANDA) process regulated by the FDA. Mark Olesnavage, Perrigo's President of Customer Business Development, stated, ``We are very pleased to receive the FDA's approval for acetaminophen extended release, an important addition to a growing segment of the analgesic category. Although this product is one of many over-the-counter pharmaceuticals Perrigo markets, it is significant because it is the first store brand product comparable to the active ingredient in Tylenol© Arthritis.' Mr. Olesnavage also stated, ``Perrigo is committed to offering its retail customers the broadest line of over-the-counter pharmaceutical and nutritional products for their store brand programs. This approval is consistent with our strategy to focus resources on the development of new products including those drugs requiring ANDA process regulatory review.' Perrigo Company is the nation's largest manufacturer of over-the-counter (non-prescription) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company's products include over-the-counter pharmaceuticals, such as analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and nutritional products, such as vitamins, nutritional supplements and nutritional drinks. Visit Perrigo on the Internet at perrigo.com .